Epstein-Barr virus antigen-derived peptide-major histocompatibility complex (EBV pMHC)

Epstein-Barr virus (EBV) antigen-derived peptides presented on major histocompatibility complex (MHC) molecules are critical targets for the immune system to identify and eliminate EBV-infected B cells and plasma cells (Nature Reviews Immunology, 2013). These complexes consist of short viral peptide fragments, derived from latent proteins such as EBNA1, LMP1, and LMP2, or lytic proteins, which are processed and loaded onto MHC Class I or II molecules for presentation on the cell surface (PubMed: 23023382). In EBV-associated malignancies like Nasopharyngeal carcinoma and Post-transplant lymphoproliferative disorder (PTLD), these pMHC complexes serve as highly specific molecular signatures that distinguish infected or transformed cells from healthy tissue (Blood, 2017). Therapeutic strategies, including adoptive T-cell therapies like tabelecleucel (Ebvallo) and investigational TCR-T cells, are designed to recognize these specific pMHC targets to induce apoptosis in the target cells (EMA, 2022). Because EBV is also strongly implicated in autoimmune conditions like multiple sclerosis, targeting these complexes is a major area of research for both oncology and immunology (Science, 2022). The efficacy of these therapies often depends on the patient's specific HLA genotype and the expression levels of the viral antigens within the target cell population (Journal of Clinical Investigation, 2015).

Other names

EBV peptide-HLA complexEBV-specific pMHCEpstein-Barr virus epitope-MHC complexEBV-derived peptide-MHCEBV-Ag-MHC

Recognition by T-cell receptors (TCRs) on cytotoxic T-lymphocytes (CTLs) or engineered T-cells, leading to the targeted apoptosis and lysis of EBV-infected cells presenting the viral peptides.